Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Utilization of Model-Informed Drug Development in Early Clinical Development: Case Study of a Hb Modulator for Treatment of Sickle Cell Disease.
Journal: CPT: pharmacometrics & systems pharmacology
Published: October 08, 2025
Priority Outcomes in Sickle Cell Disease Treatment: Co-Creation and Implementation of a Preference Exercise With Patients and Caregivers to Inform Drug Development.
Journal: Journal of patient experience
Published: November 29, 2023
Practical and Statistical Considerations for the Long Term Follow-Up of Gene Therapy Trial Participants.
Journal: Clinical pharmacology and therapeutics
Published: August 16, 2023
Evolution of Antidrug Antibody Assays During the Development of Anti-Tissue Factor Pathway Inhibitor Monoclonal Antibody Marstacimab.
Journal: The AAPS journal
Published: December 06, 2022
Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results.
Journal: British journal of haematology
Published: January 07, 2022
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia.
Journal: British journal of haematology
Published: January 07, 2022
Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies.
Journal: European journal of haematology
Published: November 08, 2021
Evaluation of biomarkers for monitoring thrombogenic potential of FXaI16L.
Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Published: November 06, 2019
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
Journal: Journal of thrombosis and haemostasis : JTH
Published: February 27, 2018
A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
Journal: Journal of thrombosis and haemostasis : JTH
Published: January 18, 2018
Last Updated: 09/26/2026